{"product_id":"radiation-oncology-in-palliative-cancer-care-isbn-9781118484159","title":"Radiation Oncology in Palliative Cancer Care","description":"\u003cp\u003e\u003cb\u003e“This textbook,\u003c\/b\u003e \u003cb\u003e\u003ci\u003eRadiation Oncology in Palliative Cancer Care\u003c\/i\u003e\u003c\/b\u003e\u003cb\u003e, represents the full evolution of radiation therapy, and of oncology in general. ( … ) [It] is an acknowledgment that palliative radiotherapy is now a sub-specialty of radiation oncology. This formally makes palliative radiotherapy a priority within patient care, academic research, quality assurance, and medical education.”\u003c\/b\u003e – From the Foreword by Nora Janjan, MD, MPSA, MBA, National Center for Policy Analysis, Dallas, TX, USA\u003c\/p\u003e \u003cp\u003ePalliative Medicine is the professional medical practice of prevention and relief of suffering and the support of the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies. The most common cause for palliative care referral is terminal cancer, and a large proportion of those referrals include patients who will need palliative radiotherapy during the course of their disease. Still, there are barriers to coordinated care between radiation oncologists and palliative care physicians that differ from one country to another. Until now, one overarching limitation to appropriate concurrent care between the specialties across all countries has been the lack of a comprehensive yet concise reference resource that educates each of the specialties about the potential synergistic effects of their cooperation. This book fills that void.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eRadiation Oncology in Palliative Cancer Care\u003c\/i\u003e:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIs the first book-length treatment of this important topic available on the market\u003c\/li\u003e \u003cli\u003eIs authored by world-renowned experts in radiation oncology and palliative medicine\u003c\/li\u003e \u003cli\u003eUses a multidisciplinary approach to content and patient treatment\u003c\/li\u003e \u003cli\u003eFeatures decision trees for palliative radiotherapy based upon factors such as patient performance status and prognosis\u003c\/li\u003e \u003cli\u003ePays careful attention to current best practices and controversies in the delivery of end-of-life cancer care\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThis book is an important resource for practicing radiation oncologists and radiation oncologists in training, as well as hospice and palliative medicine physicians and nurses, medical oncologists, and geriatricians.\u003c\/p\u003e  \u003cp\u003e\u003ci\u003eContributor list xv\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eForeword xix\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1: General principles of radiation oncology 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 A brief history of palliative radiation oncology 3\u003cbr\u003e \u003ci\u003eJoshua Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 3\u003c\/p\u003e \u003cp\u003eThe early years 3\u003c\/p\u003e \u003cp\u003eFractionation 6\u003c\/p\u003e \u003cp\u003eAdvances in radiotherapy technique: the 1950s and 1960s 7\u003c\/p\u003e \u003cp\u003eFractionation revisited: explicit palliation 10\u003c\/p\u003e \u003cp\u003eStereotactic radiotherapy 11\u003c\/p\u003e \u003cp\u003ePrognostication and tailoring palliative radiotherapy to anticipated survival 11\u003c\/p\u003e \u003cp\u003eConclusion 12\u003c\/p\u003e \u003cp\u003eReferences 13\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 The radiobiology of palliative radiation oncology 15\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eCandice A. Johnstone\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 15\u003c\/p\u003e \u003cp\u003eRadiation effect on cells 15\u003c\/p\u003e \u003cp\u003eCell cycle characteristics 18\u003c\/p\u003e \u003cp\u003eInteraction of cell cycle and radiotherapy fractionation 18\u003c\/p\u003e \u003cp\u003eRadiotherapy fractionation characteristics 19\u003c\/p\u003e \u003cp\u003eConclusion 20\u003c\/p\u003e \u003cp\u003eReferences 20\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 The physics of radiation oncology 22\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eShaun Baggarley Jiade J. Lu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 22\u003c\/p\u003e \u003cp\u003eThe development of radiation therapy technology 24\u003c\/p\u003e \u003cp\u003eProcess of radiation therapy 27\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 28\u003c\/p\u003e \u003cp\u003eConclusion 29\u003c\/p\u003e \u003cp\u003eReferences 29\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Curative intent versus palliative intent radiation oncology 31\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eVassilios Vassiliou Haris Charalambous\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 31\u003c\/p\u003e \u003cp\u003eThe determination of cure plus palliation intent versus pure palliative intent 33\u003c\/p\u003e \u003cp\u003eClinical diagnoses 35\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 38\u003c\/p\u003e \u003cp\u003eConclusion 39\u003c\/p\u003e \u003cp\u003eReferences 39\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Side effects of palliative radiotherapy 43\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAlysa Fairchild\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 43\u003c\/p\u003e \u003cp\u003eIssues with interpreting palliative radiotherapy toxicity data 44\u003c\/p\u003e \u003cp\u003eAcute side effects 45\u003c\/p\u003e \u003cp\u003eLate side effects 50\u003c\/p\u003e \u003cp\u003eAdditive toxicity 53\u003c\/p\u003e \u003cp\u003eClinical advice 53\u003c\/p\u003e \u003cp\u003eNew technologies 55\u003c\/p\u003e \u003cp\u003eChallenges in developing countries 55\u003c\/p\u003e \u003cp\u003eConclusion 56\u003c\/p\u003e \u003cp\u003eReferences 56\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2: General principles of palliation and symptom control 61\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 A history of hospice and palliative medicine 63\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMichelle Winslow Marcia Meldrum\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 63\u003c\/p\u003e \u003cp\u003eBefore the modern movement 63\u003c\/p\u003e \u003cp\u003eSt. Christopher’s and the modern hospice 64\u003c\/p\u003e \u003cp\u003ePalliative care in the United States 66\u003c\/p\u003e \u003cp\u003eGlobal development of hospice and palliative care 68\u003c\/p\u003e \u003cp\u003eContinuing challenges 69\u003c\/p\u003e \u003cp\u003eReferences 69\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Radiation therapy and hospice care 72\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eCharles F. von Gunten Frank D. Ferris and Arno J. Mundt\u003c\/i\u003e\u003cbr\u003e \u003cbr\u003e Introduction 72\u003c\/p\u003e \u003cp\u003eHospice care around the world 72\u003c\/p\u003e \u003cp\u003eHospice care in the United States 73\u003c\/p\u003e \u003cp\u003ePalliative radiation and hospice 77\u003c\/p\u003e \u003cp\u003eConclusion 79\u003c\/p\u003e \u003cp\u003eReferences 79\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 The current status of palliative care and radiotherapy 81\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eThomas Smith Susannah Batko-Yovino\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eWhat is palliative care? 81\u003c\/p\u003e \u003cp\u003eWho can benefit from palliative care? 81\u003c\/p\u003e \u003cp\u003eWhat are the goals of palliative care and what features of a palliative care program help to accomplish these goals? 83\u003c\/p\u003e \u003cp\u003eWhat is the evidence regarding the benefi ts and risks of palliative care? When should palliative care be introduced to a patient? 84\u003c\/p\u003e \u003cp\u003eAre there standards for palliative care? If so what are the defining measures? 88\u003c\/p\u003e \u003cp\u003eHow does palliative care fi t in with radiation oncology? 90\u003c\/p\u003e \u003cp\u003eReferences 92\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Palliative care in low and middle income countries: A focus on sub-Saharan Africa 95\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eHenry Ddungu Elizabeth A. Barnes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 95\u003c\/p\u003e \u003cp\u003eThe need for palliative care 95\u003c\/p\u003e \u003cp\u003eRadiotherapy 96\u003c\/p\u003e \u003cp\u003eSpecific clinical indications for palliative radiotherapy in Africa 97\u003c\/p\u003e \u003cp\u003eChallenges of palliative care delivery 98\u003c\/p\u003e \u003cp\u003eAddressing challenges to adequate palliative care 98\u003c\/p\u003e \u003cp\u003ePalliative care research 100\u003c\/p\u003e \u003cp\u003eDelivery of palliative care 101\u003c\/p\u003e \u003cp\u003eConclusion 102\u003c\/p\u003e \u003cp\u003eReferences 102\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Pain management 105\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eErin McMenamin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 105\u003c\/p\u003e \u003cp\u003ePain assessment 105\u003c\/p\u003e \u003cp\u003eAnalgesia ladder 106\u003c\/p\u003e \u003cp\u003ePrimary pharmacologic interventions 107\u003c\/p\u003e \u003cp\u003eAdjuvant medications 108\u003c\/p\u003e \u003cp\u003eEnd-of-life considerations 109\u003c\/p\u003e \u003cp\u003eConclusion 109\u003c\/p\u003e \u003cp\u003eReferences 110\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3: Locally advanced or locally recurrent diseases 113\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Primary tumors of the central nervous system 115\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eCaroline Chung Eric L. Chang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 115\u003c\/p\u003e \u003cp\u003eRadiotherapy 116\u003c\/p\u003e \u003cp\u003eSide-effect risks 120\u003c\/p\u003e \u003cp\u003eRadiotherapy limitations 120\u003c\/p\u003e \u003cp\u003eAdjuvant treatment modalities 121\u003c\/p\u003e \u003cp\u003ePromise of newer technologies 121\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 122\u003c\/p\u003e \u003cp\u003eConclusion 122\u003c\/p\u003e \u003cp\u003eReferences 122\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 The role of palliative care in head and neck cancer 126\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAlbert Tiong June Corry\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 126\u003c\/p\u003e \u003cp\u003eCurrent management of head and neck squamous cell carcinomas 126\u003c\/p\u003e \u003cp\u003ePatient selection for palliative treatment 127\u003c\/p\u003e \u003cp\u003eUse of palliative radiotherapy in head and neck squamous cell carcinomas 130\u003c\/p\u003e \u003cp\u003eRecurrent disease 134\u003c\/p\u003e \u003cp\u003eThe promise of emerging technologies 135\u003c\/p\u003e \u003cp\u003eChemotherapy in palliative head and neck squamous cell carcinomas 135\u003c\/p\u003e \u003cp\u003eNon-squamous cell carcinomas histologies 136\u003c\/p\u003e \u003cp\u003eSpecific issues in palliation of head and neck squamous cell carcinomas 137\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 138\u003c\/p\u003e \u003cp\u003eConclusion 138\u003c\/p\u003e \u003cp\u003eReferences 139\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 The role of palliative radiotherapy in breast cancer 145\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eIan H. Kunkler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 145\u003c\/p\u003e \u003cp\u003eRates of palliative loco-regional radiotherapy 148\u003c\/p\u003e \u003cp\u003eBiologic considerations 148\u003c\/p\u003e \u003cp\u003eDefinitions clinical features and multi-disciplinary approach 148\u003c\/p\u003e \u003cp\u003eClinical scenarios 150\u003c\/p\u003e \u003cp\u003eSymptom control 153\u003c\/p\u003e \u003cp\u003ePalliative loco-regional radiotherapy for oligometastatic disease 154\u003c\/p\u003e \u003cp\u003eRadiotherapy dosing schedules 154\u003c\/p\u003e \u003cp\u003eRadiotherapy technique and the promise of newer technology 156\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 158\u003c\/p\u003e \u003cp\u003eFollow up 158\u003c\/p\u003e \u003cp\u003eConclusion 159\u003c\/p\u003e \u003cp\u003eReferences 159\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Palliative radiotherapy in advanced lung cancer 163\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eGeorge Rodrigues Benjamin Movsas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 163\u003c\/p\u003e \u003cp\u003eRadiotherapy treatment 165\u003c\/p\u003e \u003cp\u003eThe impact of emerging technologies 169\u003c\/p\u003e \u003cp\u003eImportant circumstances 171\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 173\u003c\/p\u003e \u003cp\u003eConclusion 173\u003c\/p\u003e \u003cp\u003eReferences 174\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Palliative radiotherapy for gastrointestinal and colorectal cancer 177\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eRobert Glynne-Jones Mark Harrison\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 177\u003c\/p\u003e \u003cp\u003eTreatment of dysphagia 178\u003c\/p\u003e \u003cp\u003eGastric cancer 180\u003c\/p\u003e \u003cp\u003ePalliation of biliary obstruction 181\u003c\/p\u003e \u003cp\u003eNodes at origin of the superior mesenteric artery 181\u003c\/p\u003e \u003cp\u003eHigh dose rate brachytherapy 182\u003c\/p\u003e \u003cp\u003eLocally advanced\/recurrent rectal cancer 182\u003c\/p\u003e \u003cp\u003eRe-irradiation 184\u003c\/p\u003e \u003cp\u003eAnal cancer 184\u003c\/p\u003e \u003cp\u003eThe promise of highly conformal therapy 184\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 184\u003c\/p\u003e \u003cp\u003eConclusion 185\u003c\/p\u003e \u003cp\u003eReferences 185\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Genitourinary malignancies 188\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eGillian M. Duchesne\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 188\u003c\/p\u003e \u003cp\u003eIncidence and etiology 188\u003c\/p\u003e \u003cp\u003eClinical behavior 190\u003c\/p\u003e \u003cp\u003eBladder cancer 190\u003c\/p\u003e \u003cp\u003eProstate cancer 190\u003c\/p\u003e \u003cp\u003eRenal cancer 190\u003c\/p\u003e \u003cp\u003ePalliative radiotherapy and other approaches for management of primary disease 192\u003c\/p\u003e \u003cp\u003eSpecific management of metastatic disease in urologic malignancies 194\u003c\/p\u003e \u003cp\u003eThe promise of highly conformal therapy 196\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 197\u003c\/p\u003e \u003cp\u003eConclusion 197\u003c\/p\u003e \u003cp\u003eReferences 197\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Palliative radiotherapy in locally advanced and locally recurrent gynecologic cancer 199\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eFiruza Patel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 199\u003c\/p\u003e \u003cp\u003ePatterns of loco-regional failures for gynecologic cancers 200\u003c\/p\u003e \u003cp\u003eManagement 201\u003c\/p\u003e \u003cp\u003eTreatment of recurrent carcinoma of the cervix 206\u003c\/p\u003e \u003cp\u003eRecurrence after defi nitive radiation 206\u003c\/p\u003e \u003cp\u003eRecurrence after defi nitive surgery 207\u003c\/p\u003e \u003cp\u003eThe promise of newer technologies 207\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 207\u003c\/p\u003e \u003cp\u003eConclusion 208\u003c\/p\u003e \u003cp\u003eReferences 209\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Hematologic malignancies and associated conditions 210\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eDavid D. Howell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 210\u003c\/p\u003e \u003cp\u003eDiagnoses 210\u003c\/p\u003e \u003cp\u003eSpecific clinical circumstances 213\u003c\/p\u003e \u003cp\u003eLocally advanced and recurrent disease 216\u003c\/p\u003e \u003cp\u003eFuture directions 216\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 217\u003c\/p\u003e \u003cp\u003eConclusion 217\u003c\/p\u003e \u003cp\u003eReferences 217\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Pediatric palliative radiation oncology 220\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eTamara Vern-Gross\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 220\u003c\/p\u003e \u003cp\u003eDelivery of radiation treatment 221\u003c\/p\u003e \u003cp\u003eDifferences between pediatric and adult populations 222\u003c\/p\u003e \u003cp\u003eBackground 222\u003c\/p\u003e \u003cp\u003eClinical indications for palliative radiotherapy 224\u003c\/p\u003e \u003cp\u003eCaring for the pediatric patient 232\u003c\/p\u003e \u003cp\u003eBarriers to the use of palliative radiotherapy 233\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 233\u003c\/p\u003e \u003cp\u003eConclusion 234\u003c\/p\u003e \u003cp\u003eReferences 234\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4: Metastatic disease 239\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Bone metastases 241\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eYvette van der Linden Dirk Rades\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 241\u003c\/p\u003e \u003cp\u003eClinical implications and treatment modalities 241\u003c\/p\u003e \u003cp\u003eClinical symptoms 242\u003c\/p\u003e \u003cp\u003eTechnical considerations 250\u003c\/p\u003e \u003cp\u003ePrognosis and choice for treatment 250\u003c\/p\u003e \u003cp\u003eProactive approach 251\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 251\u003c\/p\u003e \u003cp\u003eConclusion 251\u003c\/p\u003e \u003cp\u003eReferences 253\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Spinal cord compression 257\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eErnesto Maranzano Fabio Trippa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 257\u003c\/p\u003e \u003cp\u003eTreatment 259\u003c\/p\u003e \u003cp\u003ePromise of newer technologies 264\u003c\/p\u003e \u003cp\u003eRe-irradiation 265\u003c\/p\u003e \u003cp\u003eSpecial considerations in developing countries 265\u003c\/p\u003e \u003cp\u003eConclusion 266\u003c\/p\u003e \u003cp\u003eReferences 267\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Brain metastases 270\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMay Tsao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 270\u003c\/p\u003e \u003cp\u003eRadiotherapy treatment 271\u003c\/p\u003e \u003cp\u003eRadiotherapy limitations 277\u003c\/p\u003e \u003cp\u003ePromise of newer technologies and areas of ongoing research 277\u003c\/p\u003e \u003cp\u003eInternational patterns of care and special considerations in developing countries 278\u003c\/p\u003e \u003cp\u003eConclusion 278\u003c\/p\u003e \u003cp\u003eReferences 279\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Liver metastases 283\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSean Bydder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 283\u003c\/p\u003e \u003cp\u003eRadiotherapy treatment 284\u003c\/p\u003e \u003cp\u003eWhole-liver radiation therapy 286\u003c\/p\u003e \u003cp\u003eConformal radiation therapy 288\u003c\/p\u003e \u003cp\u003eBrachytherapy 289\u003c\/p\u003e \u003cp\u003eSelective internal radiation therapy 289\u003c\/p\u003e \u003cp\u003eSurgery for liver metastases 290\u003c\/p\u003e \u003cp\u003eRadiofrequency ablation 290\u003c\/p\u003e \u003cp\u003ePromising new radiotherapy techniques 290\u003c\/p\u003e \u003cp\u003ePractice variation among different countries 293\u003c\/p\u003e \u003cp\u003eConclusion 294\u003c\/p\u003e \u003cp\u003eAcknowledgments 294\u003c\/p\u003e \u003cp\u003eReferences 294\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Palliative radiotherapy for malignant neuropathic pain adrenal choroidal and skin metastases 299\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eDaniel E. Roos Aaron H. Wolfson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eMalignant neuropathic pain 299\u003c\/p\u003e \u003cp\u003eAdrenal metastases 302\u003c\/p\u003e \u003cp\u003eChoroidal metastases 308\u003c\/p\u003e \u003cp\u003eSkin metastases (A.H. Wolfson) 312\u003c\/p\u003e \u003cp\u003eConclusion 314\u003c\/p\u003e \u003cp\u003eReferences 314\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5: Integration of radiation oncology and palliative care 317\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25 Design challenges in palliative radiation oncology clinical trials 319\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eDeborah Watkins Bruner Lawrence B. Berk\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 319\u003c\/p\u003e \u003cp\u003eChallenges with the validation of palliative metrics 319\u003c\/p\u003e \u003cp\u003eEvolution of palliative care clinical trials: the Radiation Therapy\u003c\/p\u003e \u003cp\u003eOncology Group experience 320\u003c\/p\u003e \u003cp\u003eInternational research efforts 325\u003c\/p\u003e \u003cp\u003eConclusion 326\u003c\/p\u003e \u003cp\u003eReferences 326\u003c\/p\u003e \u003cp\u003e\u003cb\u003e26 Radiation oncology cost-effectiveness 329\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAndre Konski\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 329\u003c\/p\u003e \u003cp\u003eCost-effectiveness 330\u003c\/p\u003e \u003cp\u003eNewer technologies 332\u003c\/p\u003e \u003cp\u003eConclusion 333\u003c\/p\u003e \u003cp\u003eReferences 333\u003c\/p\u003e \u003cp\u003e\u003cb\u003e27 Quality measures and palliative radiotherapy 335\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJames A. Hayman Rinaa S. Punglia and Anushree M. Vichare\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 335\u003c\/p\u003e \u003cp\u003eQuality measures: characteristics 336\u003c\/p\u003e \u003cp\u003eDeveloping quality measures 338\u003c\/p\u003e \u003cp\u003eDesirable attributes of quality measures 340\u003c\/p\u003e \u003cp\u003eUses of quality measures 340\u003c\/p\u003e \u003cp\u003eCurrent uses of quality measures in radiation oncology 341\u003c\/p\u003e \u003cp\u003eInternational quality measures in radiation oncology 342\u003c\/p\u003e \u003cp\u003eConclusion 343\u003c\/p\u003e \u003cp\u003eReferences 344\u003c\/p\u003e \u003cp\u003e\u003cb\u003e28 Use of technologically advanced radiation oncology techniques for palliative patients 347\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSimon S. Lo Bin S. Teh Samuel T. Chao Arjun Sahgal Nina A. Mayr and Eric L. Chang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 347\u003c\/p\u003e \u003cp\u003eOverview of technologically advanced radiotherapy techniques 347\u003c\/p\u003e \u003cp\u003eClinical applications reported in the literature 349\u003c\/p\u003e \u003cp\u003eBrain metastasis 349\u003c\/p\u003e \u003cp\u003eStereotactic radiosurgery 349\u003c\/p\u003e \u003cp\u003eScalp-sparing whole brain radiation therapy 351\u003c\/p\u003e \u003cp\u003eHippocampus-sparing whole brain radiation therapy 351\u003c\/p\u003e \u003cp\u003eStereotactic radiation therapy 351\u003c\/p\u003e \u003cp\u003eSpinal metastasis 352\u003c\/p\u003e \u003cp\u003eSpinal cord compression 352\u003c\/p\u003e \u003cp\u003eBone metastasis 355\u003c\/p\u003e \u003cp\u003eAdrenal metastasis 355\u003c\/p\u003e \u003cp\u003eToxicities associated with palliative radiotherapy using advanced technologies 356\u003c\/p\u003e \u003cp\u003e\u003ci\u003eConclusion 357\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eReferences 357\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eIndex 361\u003c\/i\u003e\u003c\/p\u003e  \u003cp\u003e“This is an excellent book that addresses a crucial aspect of radiotherapy in a way that I have not seen before. It is concise and easy to digest, but also packed with information that will help guide healthcare professionals in their practice. It would be useful for palliative care clinicians and medical oncologists, but is of particular use as a reference text to radiation oncologists and their trainees.”  (\u003ci\u003eEuropean Journal of Palliative Care\u003c\/i\u003e, 21 April 2014)\u003c\/p\u003e  \u003cp\u003e\u003cstrong\u003eStephen Lutz\u003c\/strong\u003e is one of only a small number of Radiation Oncologists who is also board certified in Hospice and Palliative Medicine.?He has served as the liaison between the US radiotherapy and palliative care communities for the past several years. His main research interests have included the formation of palliative radiotherapy treatment guidelines as well as the collaboration between the two specialties with regard to research, education, and patient advocacy. \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eEdward Chow\u003c\/strong\u003e is a Professor in the Department of Radiation Oncology at the University of Toronto?and is a senior scientist in the Sunnybrook Research Institute. He is Chair of the Rapid Response Radiotherapy Program and Bone Metastases Site Group in the Odette Cancer Center at?Sunnybrook Health Sciences Centre. \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePeter Hoskin\u003c\/strong\u003e is a UK clinical oncologist with long standing research interests in palliative radiotherapy, in particular the management of bone metastases and spinal cord compression. He was a clinical research fellow in Palliative Medicine working in opioid pharmacology before focusing his interests in clinical oncology and was Chair of the International Consensus in Palliative Radiotherapy in 2000 and ESTRO Co-chair in 2010. He has written extensively on the role of radiotherapy in palliative care in original publications and major book chapters.   \u003c\/p\u003e\u003cp\u003e\u003cb\u003e“This textbook,\u003c\/b\u003e \u003cb\u003e\u003ci\u003eRadiation Oncology in Palliative Cancer Care\u003c\/i\u003e\u003c\/b\u003e\u003cb\u003e, represents the full evolution of radiation therapy, and of oncology in general. ( … ) [It] is an acknowledgment that palliative radiotherapy is now a sub-specialty of radiation oncology. This formally makes palliative radiotherapy a priority within patient care, academic research, quality assurance, and medical education.”\u003c\/b\u003e – From the Foreword by Nora Janjan, MD, MPSA, MBA, National Center for Policy Analysis, Dallas, TX, USA\u003c\/p\u003e \u003cp\u003ePalliative Medicine is the professional medical practice of prevention and relief of suffering and the support of the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies. The most common cause for palliative care referral is terminal cancer, and a large proportion of those referrals include patients who will need palliative radiotherapy during the course of their disease. Still, there are barriers to coordinated care between radiation oncologists and palliative care physicians that differ from one country to another. Until now, one overarching limitation to appropriate concurrent care between the specialties across all countries has been the lack of a comprehensive yet concise reference resource that educates each of the specialties about the potential synergistic effects of their cooperation. This book fills that void.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eRadiation Oncology in Palliative Cancer Care\u003c\/i\u003e:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIs the first book-length treatment of this important topic available on the market\u003c\/li\u003e \u003cli\u003eIs authored by world-renowned experts in radiation oncology and palliative medicine\u003c\/li\u003e \u003cli\u003eUses a multidisciplinary approach to content and patient treatment\u003c\/li\u003e \u003cli\u003eFeatures decision trees for palliative radiotherapy based upon factors such as patient performance status and prognosis\u003c\/li\u003e \u003cli\u003ePays careful attention to current best practices and controversies in the delivery of end-of-life cancer care\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThis book is an important resource for practicing radiation oncologists and radiation oncologists in training, as well as hospice and palliative medicine physicians and nurses, medical oncologists, and geriatricians.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989904638181,"sku":"NP9781118484159","price":179.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118484159.jpg?v=1761785861","url":"https:\/\/k12savings.com\/products\/radiation-oncology-in-palliative-cancer-care-isbn-9781118484159","provider":"K12savings","version":"1.0","type":"link"}